From bench to bedside, blade, and back: FAP expression in juvenile angiofibroma. Potential implications for

Lukas Pillong1, Caroline Burgard2, Florian Rosar2

  • 1Department of Otorhinolaryngology, Head and Neck Surgery, Saarland University, 66421, Homburg, Germany. lukas.pillong@uks.eu.

Abstract

Insights

Fibroblast activation protein (FAP) is expressed in juvenile angiofibroma (JA), a rare tumor. FAPI-PET/CT imaging accurately detects FAP, showing potential for improved JA diagnosis and targeted therapy development.

Area of Science:

  • Oncology
  • Molecular Biology
  • Medical Imaging

Background:

  • Juvenile angiofibroma (JA) is a rare, benign fibrovascular tumor affecting adolescent males.
  • The biological mechanisms underlying JA are poorly understood.
  • Fibroblast activation protein (FAP) is involved in tumor progression but unstudied in JA.

Purpose of the Study:

  • To investigate FAP expression in JA.
  • To characterize the tumor microenvironment using Vimentin and PECAM1/CD31.
  • To evaluate FAPI-PET/CT imaging for JA diagnosis.

Main Methods:

  • Real-time PCR and immunohistochemistry analyzed FAP, Vimentin, and PECAM1/CD31 in JA samples.
  • FAPI-PET/CT imaging was performed preoperatively in one patient.
  • Histopathological analysis validated imaging findings.

Main Results:

  • Consistent FAP, Vimentin, and PECAM1/CD31 expression found in all JA samples.
  • Significant heterogeneity in FAP protein expression observed.
  • FAPI-PET/CT accurately identified the tumor, correlating with FAP distribution.

Conclusions:

  • This is the first study demonstrating FAP expression in JA.
  • FAPI-PET/CT imaging shows potential as a non-invasive diagnostic tool for JA.
  • Findings support further research into FAP-targeted therapies for JA.